Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 0.66 |
| ▸ | CSF1R | P07333 | 1/20 | 0.66 |
| ▸ | IGF1R | P08069 | 1/20 | 0.66 |
| ▸ | MET | P08581 | 1/20 | 0.66 |
| ▸ | KIT | P10721 | 1/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.66 |
| ▸ | SRC | P12931 | 1/20 | 0.66 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.66 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.66 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.66 |
| ▸ | TEK | Q02763 | 1/20 | 0.66 |
| ▸ | EPHA2 | P29317 | 7/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 7/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.49 |
| ▸ | EGFR | P00533 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367877 | 1.00 | KDR (1.00) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL4367282 | 0.90 | KDR (1.00) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL4367190 | 0.90 | KDR (1.00) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL4368103 | 0.85 | KDR (0.74) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL4365198 | 0.85 | KDR (0.74) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL4362208 | 0.82 | KDR (0.82) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL13861963 | 0.82 | KDR (0.82) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL4364745 | 0.81 | KDR (0.80) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL4362982 | 0.81 | KDR (1.00) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL4364757 | 0.80 | KDR (0.75) | KDRLCKCSF1RIGF1RMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | KDR 83/4885LCK 1957/4885CSF1R 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.